| EPSRC Reference: |
EP/S012265/1 |
| Title: |
An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease |
| Principal Investigator: |
McDonald, Dr T O |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Chemistry |
| Organisation: |
University of Liverpool |
| Scheme: |
Standard Research |
| Starts: |
05 April 2019 |
Ends: |
04 April 2022 |
Value (£): |
931,713
|
| EPSRC Research Topic Classifications: |
| Biomaterials |
Complex fluids & soft solids |
| Drug Formulation & Delivery |
Materials Synthesis & Growth |
|
| EPSRC Industrial Sector Classifications: |
|
| Related Grants: |
|
| Panel History: |
| Panel Date | Panel Name | Outcome |
|
01 Aug 2018
|
HT Investigator-led Panel Meeting - Aug 2018
|
Announced
|
|
|
Summary on Grant Application Form |
Within Europe, chronic diseases are currently the leading cause of mortality and morbidity. In England alone, there are 15m people with long-term conditions who are estimated to account for 70% of the total health and social care spend. A significant factor in the management of chronic disease is the long-term nature of the treatment. Although often very efficient, therapies are only effective when combined with long-term medication adherence from the patient. Unfortunately, patient adherence is typically poor within long-term disease patient populations; only about 50% of patients adhere to their treatment regimes. Poor adherence can be addressed by the simplification of therapeutic regimes through reducing the dosing frequency. For example, when self-administered treatment regimens such as oral dosing are replaced with long acting formulations adherence can be greatly improved. Additionally, reducing the frequently of dosing is known to be appealing to patients with long-term therapy requirements.
This proposal seeks to develop a new drug delivery system that could be easily injected into the body and would provide long-acting drug release. This technology would address issues caused by poor medication adherence. The drug delivery system would be composed of responsive polymer nanoparticles and drug nanoparticles that form a nanocomposite, entrapping a reservoir of drug upon injection into the body. After the drug has been released the materials would degrade into non-toxic components and leave the body.
In order to accelerate the development of this novel technology toward clinical use, this project will consist of closely-integrated materials synthesis and biological assessment. The materials involved will be simultaneously prepared and evaluated in the presence of cells to check that they are biologically compatible. The responsive polymer nanoparticles will be synthesised to combine responsive behaviour with tuneable degradation, while the design of the drug nanoparticles will allow the drug release rate to be altered. A small number of optimised materials will undergo detailed biological evaluation. The resulting novel, biodegradable, nanocomposite material would have appropriate physical and biological properties for injection into the body. This technology will provide tuneable, long-acting release of drugs for the treatment of chronic disease.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
http://www.liv.ac.uk |